Table.

Patients With CIPO Treated With Rituximab or Vedolizumab

First author (ref)	Age/sex	Additional neurological symptoms	Antibody	Intestinal pathologic examination	Cancer	Failed immunotherapies	Second-line drug and response
Coret12	60/F	Sensory neuronopathy	Hu	Not done	None	Corticosteroids, IVIG, PLEX	Rituximab. CIPO: complete response; sensory neuronopathy: partial response
Badari13	61/M	No	Hu	Diffuse lymphoplasmacytic infiltration of myenteric plexus	SCLC	IVIG, octreotide	Rituximab. Complete response (concomitant treatment with cyclophosphamide)
Drukker14	4/M	Sensory neuropathy	Hu	Lack of ganglion cells in myenteric plexus	Neuroblastoma	Prednisone	Rituximab. No responsea
Schamphelaere15	58/M	Brainstem and limbic encephalitis	Hu	T-cell infiltration of myenteric plexus	None	Prednisone and PLEX	Rituximab. No response (concomitant treatment with cyclophosphamide)
Vilaseca (patient 1)	45/M	Myasthenia gravis	None	CD8+ T cells myenteric ganglionitis, reduction of ganglionic neurons	Thymoma	Prednisone and azathioprine	Vedolizumab and low-dose prednisone. Clinical and radiologic response after 12 mo of follow-up
Vilaseca (patient 2)	7/M	Sensory neuropathy and dysautonomia	Hu	—	None	IVIg	Vedolizumab. No response
Vilaseca (patient 3)	19/F	No	Hu	CD8+ T cells myenteric ganglionitis, reduction of ganglionic neurons	None	Prednisone, adalimumab	Methylprednisolone, IVIg, rituximab. Clinical and radiologic response after 12 mo of follow-up
Vilaseca (patient 4)	66/F	No	None	T-cell infiltration myenteric ganglionitis	None	Prednisone	Vedolizumab. Clinical and radiologic response after 12 mo of follow-up

Abbreviations: CIPO = Chronic Intestinal Pseudo-obstruction; IVIg = IV immunoglobulins; PLEX = plasma exchange; SCLC = small cell lung cancer.

^aPLEX induced a CIPO remission that was initially maintained by rituximab. Despite this treatment there were 4 relapses over the ensuing 17 months.